Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
Aug 28, 2017
-- Immediately Positions Gilead as a Leader in Cell Therapy -- -- Kite's Lead CAR T Therapy Candidate, Axicabtagene Ciloleucel, Under Priority Review in the U.S. and Expedited Review in the EU -- -- Provides Broad Pipeline in Hematologic Malignances and Solid Tumors and Robust Plat...
Aug 17, 2017
Study Demonstrates the Potential of TCR Engineered T-Cell Therapy to Induce Remissions in Solid Tumors KITE-718, Utilizing Same TCR Construct and Next-Generation T-Cell Manufacturing Technology, Currently Enrolling SANTA MONICA, Calif.--(BU...
Aug 8, 2017
Filed Industry's First CAR-T Marketing Authorization Application in Europe for Axicabtagene Ciloleucel for Potential EU Approval and Launch in 2018 Submitted Investigational New Drug Application for KITE-585, a CAR-T Candidate that Targets BCMA in Multiple Myeloma ...
Aug 8, 2017
Internally Generated Cell Therapy Candidate Engineered with Fully Human Anti-BCMA Construct Next-Generation Manufacturing Process Designed for Enhanced Product Potency and Activity SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc. (Nasdaq:...
Aug 7, 2017
First Patient Dosed in Safety Expansion Cohort of ZUMA-1 in the European Union (EU) Axicabtagene Ciloleucel Being Developed Under Priority Medicines (PRIME) Designation in the EU Marketing Authorization Application to the European Medicines Agency for Axi...
Aug 3, 2017
Retrospective Study Includes 636 Patients with Refractory Aggressive Non-Hodgkin Lymphoma from Four Major Institutional Databases Findings Highlight Need for New Therapeutic Options as Patients Achieved Only a 7 Percent Complete Response Rate and Median Overall Survival of 6.3 Months w...
Aug 2, 2017
ZUMA-5 Expands Axi-Cel Clinical Program Targeting B-Cell Malignancies Indolent B-Cell NHL (iNHL) Estimated to Comprise Approximately 25 Percent of All 2017 Newly Diagnosed NHL Cases, with Follicular Lymphoma (FL) Being the Most Common Subtype First Multi-Center CAR-...
Aug 1, 2017
SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc. (Nasdaq:KITE), a leading cell therapy company, today announced that management will present at the Canaccord Genuity 37th Annual Growth Conference on Wednesday, August 9, 2017 at 2:00 pm Eastern Time in Boston, MA. A live audio web...
Aug 1, 2017
Conference Call and Webcast Scheduled for 8:30 AM ET / 5:30 AM PT SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc. (Nasdaq:KITE), a leading cell therapy company, today announced that it will report second quarter 2017 financial results on Tuesday, August 8, 2017, prior to the open o...
Jul 31, 2017
Submission Based on Primary Analysis of ZUMA-1 in Patients with Aggressive NHL Accelerated Assessment Granted Through Priority Medicines (PRIME) Regulatory Initiative SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc. (Nasdaq:KITE), a leadi...
Jul 20, 2017
Durable CRs Continued After Recovery of Normal B Cells Anti-CD19 CAR T-cell Therapy Can Be Curative for Chemorefractory Aggressive NHL SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc. (Nasdaq:KITE), a leading cell therapy company, highlight...
Jun 28, 2017
SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc., (Nasdaq:KITE), a leading cell therapy company, today announced that the United States Patent and Trademark Office (USPTO) has provided a Notice of Intent to issue an Ex Parte Reexamination Certificate that confirms the patentability of amended claims pres...
Jun 27, 2017
SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc., (Nasdaq:KITE), a leading cell therapy company, has been named to MIT Technology Review's 2017 list of 50 Smartest Companies. To make the list, a company must exhibit technological leadership and business acumen which sets them apart from competitors. ...
Jun 6, 2017
SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc., (Nasdaq:KITE), a leading cell therapy company, today announced that management will present at two investor conferences in June 2017: Jefferies 2017 Global Healthcare ConferenceWednesday, June 71:30pm Eastern TimeNew...
Jun 5, 2017
Remissions Ongoing From 2.0 to Greater than 7.4 Months KTE-C19 Successfully Manufactured in Six Days Across a Range of Absolute Lymphocyte and Blast Counts Phase 2 Initiation Planned for 2017 SANTA MONICA, Calif.--(BUSINESS WIRE)-- ...
Page:
...
Next Last
 
= add release to Briefcase